Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration

British Journal of Ophthalmology

Volumn 96, Issue 12, 2012, Pages 1479-1483

  Querques, Giuseppe ^a   Massamba, Nathalie ^a   Coscas, Florence ^a   Forte, Raimondo ^a   Souied, Eric H ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; BEST CORRECTED VISUAL ACUITY; CASE STUDY; CATARACT; CLINICAL ARTICLE; DISEASE COURSE; DRUG RESPONSE; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GEOGRAPHIC ATROPHY; HUMAN; INTERVENTION STUDY; INTRARETINAL CYSTIC LESION; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GEOGRAPHIC ATROPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84869869866     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302191     Document Type: Review

References (13)

1. Coleman HR, Chan CC, Ferris FL III, et al. Age-related macular degeneration. Lancet 2008;372:1835-45.
2. Bird AC, Bressler NM, Bressler SB, et al. The International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995;39:367-74.
3. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81.
4. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
5. Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
6. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010;94:292-6.
7. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
8. Siegel S, Castellan NJ Jr. Nominally scaled data and the kappa statistics K. In: Anker JD. Nonparametric statistics for the behavioral sciences. 2nd edn. New York: McGraw-Hill, 1988:284-91.
9. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol 1993;46:423-9.
10. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
11. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age- related macular degeneration. Am J Ophthalmol 2009;147:831-7.
12. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
13. Saint-Geniez M, Kurihara T, Sekiyama E, et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 2009;106:18751-6.